Needham Reiterates Buy on Cogent Biosciences, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Cogent Biosciences (NASDAQ:COGT) and maintained a price target of $22.
September 19, 2023 | 9:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cogent Biosciences' stock rating has been reiterated as 'Buy' by Needham analyst Ami Fadia, with a maintained price target of $22.
The reiteration of a 'Buy' rating by a Needham analyst indicates a positive outlook for Cogent Biosciences. The maintained price target of $22 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100